Juno Presents TRANSCEND NHL 001 Trial Data At International Conference On Malignant Lymphoma

– 66% (21/32) overall response and 50% (16/32) complete response at three months in core group moving to pivotal trial; of those patients in response at three months, 90% (9/10) continue in response at six months

– 66% (29/44) of patients experienced no cytokine release syndrome or neurotoxicity in core group moving into pivotal trial

– 18% (8/44) of core group patients experienced severe neurotoxicity and 2% (1/44) experienced severe cytokine release syndrome

– Defined cell composition and 4-1BB co-stimulatory domain, a combination unique to Juno, deliver predictable cell expansion and prolonged CAR T cell persistence

– Product was available for 98% (86/88) of patients

– Data originally presented at ASCO 2017

SEATTLE--(BUSINESS WIRE)--Juno Therapeutics, Inc. (NASDAQ: JUNO), a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today presented data from the TRANSCEND trial of JCAR017 in relapsed and refractory (r/r) aggressive B cell non-Hodgkin lymphoma (NHL) at the 2017 International Conference on Malignant Lymphoma in Lugano, Switzerland.

JCAR017 is Juno’s investigative chimeric antigen receptor (CAR) T cell product candidate that targets CD19, a protein expressed on the surface of almost all B cell malignancies, and uses a defined composition of CD4 to CD8 T cells and a 4-1BB costimulatory domain, which differentiates it from other current CD19-directed CAR T product candidates. JCAR017 has been granted Breakthrough Therapy designation by the FDA for treatment of r/r aggressive large B cell NHL and PRIME designation by the European Medicines Agency for treatment of r/r diffuse large B cell lymphoma (DLBCL), a type of NHL.

“We are pleased to again present TRANSCEND data, which show compelling results in the treatment of aggressive relapsed or refractory NHL,” said Sunil Agarwal, M.D., Juno’s President of Research and Development. “High rates of durable responses and the early survival data are especially exciting, as is the emerging safety profile. The majority of TRANSCEND patients experienced no cytokine release syndrome or neurotoxicity at all. While still early, these data suggest that JCAR017 could be administered on an outpatient basis.”

Data were presented by Jeremy Abramson, M.D., of Massachusetts General Hospital Cancer Center, from the multicenter TRANSCEND trial (ABSTRACT #128), a Phase 1 study that has treated a total of 67 patients with r/r aggressive B cell NHL, including those with DLBCL or follicular lymphoma grade 3B, as of a data cutoff date of May 4, 2017.

TRANSCEND NHL 001 is a dose-finding study of JCAR017, which is administered following fludarabine/cyclophosphamide lymphodepletion. Patients received one of two dose levels (50 or 100 million cells). They were then evaluated for pharmacokinetics, disease response, and safety outcomes, including common CAR T side effects such as cytokine release syndrome (CRS) and neurotoxicity (NT).

Notably, the TRANSCEND NHL 001 protocol includes patients with forms of B cell NHL that would exclude them from trials of other CAR T product candidates, including those with ECOG 2 performance status, central nervous system (CNS) involvement of their lymphoma, and those relapsed after allogeneic bone marrow transplant.

Data for the DLBCL cohort were presented in two groups: core and full. The core analysis group (N=44) includes patients that represent the population that Juno plans to move forward into a pivotal trial in the second half of 2017. The core group includes patients with DLBCL (de novo and transformed from follicular lymphoma) that are ECOG Performance Status 0-1. The full analysis group includes all r/r patients in the DLBCL cohort (N=55), including 11 patients with poor performance status or niche subtypes of aggressive NHL. Both the core and full groups received conforming product, with at least one month follow-up, and with a data cutoff date of May 4, 2017, for this presentation.

“CAR T cell therapy represents an important step forward in providing options for these highly chemotherapy refractory patients and addresses a significant unmet medical need,” said Dr. Abramson. “I am particularly excited about the emerging efficacy and safety profile with JCAR017, which could ultimately prove to be optimal therapy for patients with relapsed and refractory DLBCL.”

Key data and findings:

Core Group (N=44)

  • Combining data across dose levels:
    • Overall response rate (ORR) is 86% (38/44) and the complete response (CR) is 59% (26/44).
    • Three-month ORR is 66% (21/32) and CR is 50% (16/32). Of patients in response at three months, 90% (9/10) continue in response at six months.
  • Early data suggest a dose response relationship at three months:
    • Dose level 1 (50 million cells) ORR is 58% (11/19) and CR is 42% (8/19).
    • Dose level 2 (100 million cells) ORR is 78% (7/9) and CR is 56% (5/9).
  • 97% (37/38) of responding patients are alive and in follow-up as of May 4, 2017.
  • 2% (1/44) experienced severe CRS and 18% (8/44) experienced severe NT.
  • 66% (29/44) did not experience any CRS or NT. No deaths were reported from CRS or NT.
  • There was one Grade 5 adverse event of diffuse alveolar damage, which the investigator assessed as possibly related to fludarabine, cyclophosphamide, and JCAR017 treatment, occurring on day 23 in an 82-year-old subject who refused mechanical ventilation for progressive respiratory failure while neutropenic on growth factors and broad spectrum antibiotics and antifungals. This patient had no CRS and Grade 3 neurotoxicity resolution before the Grade 5 event.

Full Dataset (N=55)

  • Combining data across dose levels:
    • Best ORR is 76% (41/54) and CR is 52% (28/54).
    • Three-month ORR is 51% (21/41) and CR is 39% (16/41).
  • 2% (1/55) experienced severe CRS and 16% (9/55) experienced severe NT. 60% (33/55) did not experience any CRS or NT. No deaths reported from CRS or NT.
  • Early data do not suggest a dose toxicity relationship at the doses tested:
    • Severe CRS rate is 3% (1/30) at dose level 1 and 0% (0/19) at dose level 2.
    • Severe NT rate is 20% (6/30) at dose level 1 and 11% (2/19) at dose level 2.
  • 11% (6/55) received tocilizumab and 24% (13/55) received dexamethasone.
  • The most frequently reported treatment-emergent adverse events were neutropenia (35%), CRS (35%), and fatigue (31%).


Product was available for 98% (86/88) of patients apheresed. TRANSCEND patients receive product made at JuMP, Juno’s manufacturing facility in Bothell, Washington. Juno expects commercial production will be accomplished in less than 21 days, and Juno is investing in manufacturing infrastructure to enable a smooth prescribing experience with a reliable delivery time at market entry.

About Juno’s Chimeric Antigen Receptor (CAR) and T Cell Receptor (TCR) Technologies

Juno’s CAR and TCR technologies genetically engineer T cells to recognize and kill cancer cells. Juno’s CAR T cell technology inserts a gene for a particular CAR into the T cell, enabling it to recognize cancer cells based on the expression of a specific protein located on the cell surface. Juno’s TCR technology provides the T cells with a specific T cell receptor to recognize protein fragments derived from either the surface or inside the cell. When either type of engineered T cell engages the target protein on the cancer cell, it initiates a cell-killing response against the cancer cell. JCAR014 and JCAR017 are investigational product candidates and their safety and efficacy have not been established.

About Juno

Juno Therapeutics is building a fully integrated biopharmaceutical company focused on developing innovative cellular immunotherapies for the treatment of cancer. Founded on the vision that the use of human cells as therapeutic entities will drive one of the next important phases in medicine, Juno is developing cell-based cancer immunotherapies based on chimeric antigen receptor and high-affinity T cell receptor technologies to genetically engineer T cells to recognize and kill cancer. Juno is developing multiple cell-based product candidates to treat a variety of B cell malignancies as well as solid tumors. Several product candidates have shown compelling clinical responses in clinical trials in refractory leukemia and lymphoma conducted to date. Juno's long-term aim is to leverage its cell-based platform to develop new product candidates that address a broader range of cancers and human diseases. Juno brings together innovative technologies from some of the world's leading research institutions, including the Fred Hutchinson Cancer Research Center, Memorial Sloan Kettering Cancer Center, Seattle Children's Research Institute (SCRI), the University of California, San Francisco, and The National Cancer Institute. Juno Therapeutics has an exclusive license to the St. Jude Children’s Research Hospital patented technology for CD19-directed product candidates that use 4-1BB, which was developed by Dario Campana, Chihaya Imai, and St. Jude Children’s Research Hospital. Juno’s product candidate JCAR017 was developed in collaboration with SCRI and others.

About the Juno-Celgene Collaboration

Celgene Corporation and Juno Therapeutics formed a collaboration in June 2015, under which the two companies will leverage T cell therapeutic strategies to develop treatments for patients with cancer and autoimmune diseases with an initial focus on chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies. In April 2016, Celgene exercised its option to develop and commercialize the Juno CD19 program outside North America and China.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, including statements regarding Juno’s mission, clinical trial results and the implications thereof, the potential for outpatient administration of JCAR017, clinical trial plans, future benefits to patients, projected commercial production time, Juno’s ability to enable a smooth prescribing experience with a reliable delivery time at market entry, and the potential of the Celgene collaboration. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from such forward-looking statements, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to, risks associated with: the success, cost, and timing of Juno's product development activities and clinical trials; Juno's ability to obtain regulatory approval for and to commercialize its product candidates; Juno's ability to establish a commercially-viable manufacturing process and manufacturing infrastructure; regulatory requirements and regulatory developments; success of Juno's competitors with respect to competing treatments and technologies; Juno's dependence on third-party collaborators and other contractors in Juno's research and development activities, including for the conduct of clinical trials and the manufacture of Juno's product candidates; Juno's dependence on Celgene for the development and commercialization outside of North America and China of Juno’s CD19 product candidates and any other product candidates for which Celgene exercises an option; Juno’s dependence on JW Biotechnology (Shanghai) Co., Ltd., over which Juno does not exercise complete control, for the development and commercialization of product candidates in China; and Juno's ability to obtain, maintain, or protect intellectual property rights related to its product candidates; amongst others. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Juno's business in general, see Juno's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 4, 2017, and Juno’s other periodic reports filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Juno disclaims any obligation to update these forward-looking statements.

Juno Therapeutics, Inc.
Investor Relations:
Nicole Keith, 206-566-5521
Christopher Williams, 206-566-5660

Back to news